Document Detail


Docetaxel-associated epiphora.
MedLine Citation:
PMID:  16716138     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Docetaxel is a semisynthetic taxane indicated for the treatment of advanced breast, prostate, and non-small cell lung cancers; it is also used for the treatment of various other solid tumors. The standard intermittent dosage of docetaxel is 60-100 mg/m2 every 3 weeks. At this dose and schedule, myelosuppression is common and neutropenia is usually the dose-limiting toxicity. Weekly administration of docetaxel 20-42 mg/m2 is being tested in the treatment of advanced solid tumors in order to improve patient tolerance by reducing the interval dose and to maintain therapeutic efficacy by increasing overall dose intensity. Asthenia and peripheral neuropathy can limit continued administration of weekly docetaxel. Epiphora (excess tearing due to narrowing or blockage of the lacrimal outflow passages) is associated with repeated weekly administration of docetaxel. This adverse effect can interfere with activities of daily life and negatively affect quality of life. Epiphora may be an underreported adverse effect of treatment because of underrecognition by clinicians and patient embarrassment with respect to seemingly uncontrolled tearing. The use of weekly docetaxel administration is expanding; therefore, patients should be educated to recognize and report signs and symptoms of epiphora. It is important for clinicians participating in the care of patients undergoing treatment with docetaxel to monitor for excess tearing and signs of eye irritation to ensure timely management of treatment-related epiphora.
Authors:
Polly E Kintzel; Laura B Michaud; Marianne K Lange
Related Documents :
12720148 - Radioimmunotherapy for waldenstrom's macroglobulinemia.
15090738 - Phase i clinical and pharmacokinetic study of bbr 3576, a novel aza-anthrapyrazole, adm...
1732038 - Pediatric phase i trial, pharmacokinetic study, and limited sampling strategy for pirit...
16421428 - Phase i trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib...
11438328 - Ovarian function during and after treatment with the new progestagen org 30659.
11122388 - Frequency of inhibitor development in severe haemophilia a children treated with cryopr...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  26     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-23     Completed Date:  2006-11-22     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  853-67     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Spectrum Health Hospitals, Grand Rapids, Michigan 49503, and Division of Pharmacy, University of Texas M. D. Anderson Cancer Center, Houston, USA. polly.kintzel@spectrum-health.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / administration & dosage,  adverse effects*
Female
Humans
Lacrimal Apparatus / drug effects,  pathology
Lacrimal Duct Obstruction / chemically induced*
Male
Taxoids / administration & dosage,  adverse effects*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Taxoids; 15H5577CQD/docetaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's diseas...
Next Document:  Leflunomide and warfarin interaction: case report and review of the literature.